The nCounter® PanCancer Progression panel (NanoString Technologies Inc., Seattle WA) is comprised of 740 genes related to cancer progression processes including angiogenesis, extracellular matrix remodeling (ECM), EMT, tumor growth, and metastasis. Details for the probes included in the Progression panel are available on request from NanoString Technologies Inc. using the form at http://www.nanostring.com/support-documents/ncounter-pancancer-progression-panel-gene-list/. We also designed a custom panel of 69 genes related to arylamine exposure and bladder cancer plus 30 housekeeping genes, 8 negative controls, and 6 spike-in hybridization/positive controls overlapping with those in the Progression panel. The custom genes and their annotations are listed in Supplementary Table S2. Genes in the custom panel were selected from in vitro and in vivo arylamine exposure studies [19 (link)–21 (link), 23 (link), 24 (link)] and include 25 genes related to the DNA damage signaling pathway [19 (link), 23 (link)] and 4 genes related to EMT [20 (link), 25 (link)]. We also included several genes related to bladder cancer from The Cancer Genome Atlas (TCGA) [26 (link)–28 (link)], which are highlighted in the Supplementary Table S2.
Free full text: Click here